Monte Rosa has unveiled new data from two trials of its pipeline of molecular glue degraders, notably MRT-6160 and MRT-23.

DelveInsight's Molecular Glues Market Insights report includes a comprehensive understanding of current treatment practices, ...

The recent approvals and robust pipeline activity are expected to fuel the market of molecular glues in the 7MM during the forecast period 2025-2034 due to factors like improved diagnosis, treatment ...

Monte Rosa Therapeutics, a US biotech developing novel molecular glue degrader (MGD)-based medicines, closed Thursday’s ...

Potentially best-in-class RAS-targeting franchise advancing with both ERAS-0015 and ERAS-4001 expected to enter the clinic in 2025Ongoing Phase 3 ...

Monte Rosa's in-house pipeline is led by MRT-2359, a molecular glue degrader that breaks down a protein called GSPT1 and is in phase 1/2 trials as a potential treatment for lung cancer and other ...

So now let's turn to the I&I program starting with MRT-6160 our VAV1 directed molecular glue degrader ... reductions of CRP levels in clinical trials. Therefore, we think an exome degrader ...

“It is really rewarding to now watch the first RIPTAC enter clinical trials,” says Craig Crews ... expects that compact molecular glue compounds can provide RIPTAC-like tissue specificity ...

KPG-818 is a novel oral molecular glue modulator of the E3 ubiquitin ligase ... KPG-818 possesses immunomodulatory, anti-angiogenic, and anti-tumor effects. The phase I clinical trial of KPG-818 in ...